KURA Oncology amends equity plan to increase shares by 1.46M and grants PSUs to executives

Kura Oncology, Inc.

Board approved amendment to 2014 Equity Incentive Plan to increase shares by 1,459,800, subject to stockholder approval at 2023 Annual Meeting.
Compensation Committee and Board granted PSUs totaling 1,235,100 shares to five executive officers, contingent on stockholder approval of amendment.
PSU vesting tied to milestones: FDA NDA approval for ziftomenib in AML, initiation of registration-enabling trial, and Phase 2 start of farnesyl transferase inhibitor combination.
Executive officers receiving PSUs: CEO Troy Wilson (547,500), CLO Teresa Bair (146,700), CMO Stephen Dale (247,500), CCO Kirsten Flowers (146,700), COO Kathleen Ford (146,700).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.